The everolimus eluting Synergy Megatron^TM drug‐eluting stent platform: Early outcomes from the European Synergy Megatron^TM Implanters' Registry

Abstract

BackgroundThe Synergy MegatronTM is an everolimus‐drug eluting stent that may offer advantages in the treatment of aorto‐ostial disease and large proximal vessels.AimsTo report the short‐ to medium‐term clinical outcomes from the European Synergy MegatronTM Implanters' Registry.MethodsThis registry was an investigator‐initiated study conducted at 14 European centers. The primary outcome was target lesion failure (TLF), defined as the composite of cardiovascular death, target vessel myocardial infarction (MI), and target lesion revascularisation.ResultsFive hundred seventy‐five patients underwent PCI with MegatronTM between 2019 and 2021. Patients were 69 ± 12 years old, 26% had diabetes mellitus, 24% had moderate‐severe left ventricular impairment and 59% presented with an acute coronary syndrome. 15% were deemed prohibitively high risk for surgical revascularisation. The target vessel involved the left main stem in 55%, the ostium of the RCA in 13% and was a true bifurcation (Medina 1,1,1) in 50%. At 1 year, TLF was observed in 40 patients, with 26 (65%) occurring within the first 30 days. The cumulative incidence of TLF was 4.5% at 30 days and 8.6% (95% CI 6.3–11.7) at 1 year. The incidence of stent thrombosis was 0.5% with no late stent thromboses. By multivariate analysis, the strongest independent predictors of TLF were severe left ventricular impairment (HR 3.43, 95% CI: 1.67–6.76, p < 0.001) and a target vessel involving the left main (HR 4.00 95% CI 1.81–10.15 p = 0.001).ConclusionsUse of the Synergy MegatronTM everolimus eluting stent in a ‘real‐world’ setting shows favorable outcomes at 30 days and 1 year.